| Nabriva Therapeutics US, Inc. |
72000011010 |
Xenleta 600 mg tablets blister pack 10 |
2021-11-10 |
1375.0000 |
Nabriva pricing decisions regarding the WAC price of a medication are determined after consideration of many factors, including clinical and economic value of the particular therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers in both the commercial and government channels, patient support to ensure patient access to life-saving and life-changing medications, overall research and development costs. |
None |
28 |
None |
None |
None |
None |
None |
None |
None |
None |
| Neurocrine Biosciences, Inc. |
70370106001 |
INGREZZA 60 MG CAPSULES |
2021-06-01 |
7043.0000 |
We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, insurers and society. In so doing, we adhere to the highest ethical and compliance standards and are guided by the following principles:
• Improving the lives and well-being of patients
• Maximizing access and reducing out-of-pocket costs for eligible patients
• Striving to reduce obstacles for patients to fill a prescription or undergo treatment
• Fueling the discovery and development of life-changing medicines |
None |
500000 |
1 |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Neurocrine Biosciences, Inc. is limiting its response to that which is otherwise in the public domain or publicly available. Marketing Plans are not in the public domain or publicly available. This drug was developed in-house and was not acquired. Tardive Dyskinesia affects an estimated 500,000 people in the U.S. |
None |
| Nostrum Laboratories, Inc. |
29033021401 |
Carisoprodol 100ct 350mg Tablets in 1 Bottle |
2021-01-25 |
808.8500 |
None |
1 |
5000 |
None |
None |
None |
None |
None |
None |
This product is drug listed but has not yet been sold/entered the market. Nostrum Labs expects to begin selling this product/launch the product in the next two months. |
None |
| Novartis |
00078109120 |
SCEMBLIX 20 mg, 60 tablets |
2021-10-29 |
17900.0000 |
The marketing for SCEMBLIX includes education and promotion to physicians, direct to consumer promotions, other types of marketing (e.g., online platforms and education). Novartis considered many factors in determining the price of SCEMBLIX. SCEMBLIX is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket, and represents an important development for patients who experience resistance and/or intolerance to currently available TKI therapies1-3. We priced in parity to other branded treatments in this therapeutic area and are focused on access to SCEMBLIX i for this patient population. |
None |
61700 |
1 |
1 |
None |
None |
None |
None |
Novartis estimates there are 61700 patients with Chronic Myeloid Leukemia in the United States. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078109820 |
SCEMBLIX 40 mg, 60 tablets |
2021-10-29 |
17900.0000 |
The marketing for SCEMBLIX includes education and promotion to physicians, direct to consumer promotions, other types of marketing (e.g., online platforms and education). Novartis considered many factors in determining the price of SCEMBLIX. SCEMBLIX is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket, and represents an important development for patients who experience resistance and/or intolerance to currently available TKI therapies1-3. We priced in parity to other branded treatments in this therapeutic area and are focused on access to SCEMBLIX i for this patient population. |
None |
61700 |
1 |
1 |
None |
None |
None |
None |
Novartis estimates there are 61700 patients with Chronic Myeloid Leukemia in the United States. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novartis |
00078100060 |
LEQVIO (Inclisiran 284mg subcutaneous injection) |
2021-12-22 |
3250.0000 |
Novartis considered many factors in determining the price of LEQVIO. LEQVIO is a first-in-class siRNA and is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C). We priced in parity to other branded treatments in this therapeutic area and are focused on access to LEQVIO for this patient population. |
None |
30000000 |
None |
None |
None |
None |
None |
None |
Novartis estimates there are 30,000,000 diagnosed prevalent patients with ASCVD in the United States.
In January 2020, Novartis acquired The Medicines Company for $9.7 billion which included the global rights to develop, manufacture, and commercialize inclisiran under a license and collaboration agreement with Alnylam Pharmaceuticals. During the acquisition and integration of the company, The Medicines Company submitted the New Drug Application for inclisiran in December 2019.
Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
None |
| Novo |
00169452514 |
Wegovy™ 0.25 mg/0.5 mL in 1 pre-filled pen; 4 pens in 1 carton |
2021-06-15 |
1349.0200 |
None |
1 |
2600000 |
None |
1 |
None |
None |
None |
None |
Wegovy™ is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). The Prescribing Information for Wegovy™, is available at: https://www.novo-pi.com/wegovy.pdf.
Regarding the reported patient estimate, per IQVIA’s Longitudinal Access and Adjudication Database, citing 2020 year data, there are currently 2.6 million patients on pharmacotherapy medication for anti-obesity in the US. For the estimated patients requirement, Novo Nordisk utilizes this number of estimated patients on pharmacotherapy, however, we note that the total number of patients diagnosed with obesity is roughly 30 million, the majority of those patients will not go onto an anti-obesity pharmacotherapy treatment. Please note, this is not an estimate of prescriptions that might be written for Wegovy™ or each available dose of Wegovy™. Wegovy™ will represent a portion of the broader market for anti-obesity therapies.
Wegovy™ was developed by Novo Nordisk. |
None |
| Novo |
00169450514 |
Wegovy™ 0.5 mg/0.5 mL in 1 pre-filled pen; 4 pens in 1 carton |
2021-06-15 |
1349.0200 |
None |
1 |
2600000 |
None |
1 |
None |
None |
None |
None |
Wegovy™ is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). The Prescribing Information for Wegovy™, is available at: https://www.novo-pi.com/wegovy.pdf.
Regarding the reported patient estimate, per IQVIA’s Longitudinal Access and Adjudication Database, citing 2020 year data, there are currently 2.6 million patients on pharmacotherapy medication for anti-obesity in the US. For the estimated patients requirement, Novo Nordisk utilizes this number of estimated patients on pharmacotherapy, however, we note that the total number of patients diagnosed with obesity is roughly 30 million, the majority of those patients will not go onto an anti-obesity pharmacotherapy treatment. Please note, this is not an estimate of prescriptions that might be written for Wegovy™ or each available dose of Wegovy™. Wegovy™ will represent a portion of the broader market for anti-obesity therapies.
Wegovy™ was developed by Novo Nordisk. |
None |
| Novo |
00169450114 |
Wegovy™ 1 mg/ 0.5 mL in 1 pre-filled pen; 4 pens in 1 carton |
2021-06-15 |
1349.0200 |
None |
1 |
2600000 |
None |
1 |
None |
None |
None |
None |
Wegovy™ is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). The Prescribing Information for Wegovy™, is available at: https://www.novo-pi.com/wegovy.pdf.
Regarding the reported patient estimate, per IQVIA’s Longitudinal Access and Adjudication Database, citing 2020 year data, there are currently 2.6 million patients on pharmacotherapy medication for anti-obesity in the US. For the estimated patients requirement, Novo Nordisk utilizes this number of estimated patients on pharmacotherapy, however, we note that the total number of patients diagnosed with obesity is roughly 30 million, the majority of those patients will not go onto an anti-obesity pharmacotherapy treatment. Please note, this is not an estimate of prescriptions that might be written for Wegovy™ or each available dose of Wegovy™. Wegovy™ will represent a portion of the broader market for anti-obesity therapies.
Wegovy™ was developed by Novo Nordisk. |
None |
| Novo |
00169451714 |
Wegovy™ 1.7 mg/0.75 mL in 1 pre-filled pen; 4 pens in 1 carton |
2021-06-15 |
1349.0200 |
None |
1 |
2600000 |
None |
1 |
None |
None |
None |
None |
Wegovy™ is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). The Prescribing Information for Wegovy™, is available at: https://www.novo-pi.com/wegovy.pdf.
Regarding the reported patient estimate, per IQVIA’s Longitudinal Access and Adjudication Database, citing 2020 year data, there are currently 2.6 million patients on pharmacotherapy medication for anti-obesity in the US. For the estimated patients requirement, Novo Nordisk utilizes this number of estimated patients on pharmacotherapy, however, we note that the total number of patients diagnosed with obesity is roughly 30 million, the majority of those patients will not go onto an anti-obesity pharmacotherapy treatment. Please note, this is not an estimate of prescriptions that might be written for Wegovy™ or each available dose of Wegovy™. Wegovy™ will represent a portion of the broader market for anti-obesity therapies.
Wegovy™ was developed by Novo Nordisk. |
None |
| Novo |
00169452414 |
Wegovy™ 2.4 mg/0.75 mL in 1 pre-filled pen; 4 pens in 1 carton |
2021-06-15 |
1349.0200 |
None |
1 |
2600000 |
None |
1 |
None |
None |
None |
None |
Wegovy™ is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). The Prescribing Information for Wegovy™, is available at: https://www.novo-pi.com/wegovy.pdf.
Regarding the reported patient estimate, per IQVIA’s Longitudinal Access and Adjudication Database, citing 2020 year data, there are currently 2.6 million patients on pharmacotherapy medication for anti-obesity in the US. For the estimated patients requirement, Novo Nordisk utilizes this number of estimated patients on pharmacotherapy, however, we note that the total number of patients diagnosed with obesity is roughly 30 million, the majority of those patients will not go onto an anti-obesity pharmacotherapy treatment. Please note, this is not an estimate of prescriptions that might be written for Wegovy™ or each available dose of Wegovy™. Wegovy™ will represent a portion of the broader market for anti-obesity therapies.
Wegovy™ was developed by Novo Nordisk. |
None |